Press Release
October 4, 2023

Teva and Sanofi Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment, with $500 Million Upfront and up to $1 Billion in Milestones

The Life Sciences team advised Teva Pharmaceuticals in its collaboration with Sanofi to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.

Under the terms of the new collaboration agreement, Teva will receive an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in development and launch milestones. Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement and Sanofi will lead the development of the Phase 3 program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.

Teva has been developing and producing medicines to improve people’s lives for more than a century.

The Goodwin team was led by Shane Albright, Alan (Zhenghui) Wang, Elliot Horlick and Kingsley Taft, with invaluable assistance from Susan Lee.

For more details, read the press release and coverage in Bloomberg, Endpoints News, Fierce Biotech, MarketWatch and Reuters.